1. Sleeping BeautymRNA-LNP enables stable rAAV transgene expression in mouse and NHP hepatocytes and improves vector potency
- Author
-
Zakas, Philip M., Cunningham, Sharon C., Doherty, Ann, van Dijk, Eva B., Ibraheim, Raed, Yu, Stephanie, Mekonnen, Befikadu D., Lang, Brendan, English, Elizabeth J., Sun, Gang, Duncan, Miles C., Benczkowski, Matthew S., Altshuler, Robert C., Singh, Malvenderjit Jagjit, Kibbler, Emily S., Tonga, Gulen Y., Wang, Zi Jun, Wang, Z. Jane, Li, Guangde, An, Ding, Rottman, James B., Bhavsar, Yashvi, Purcell, Cormac, Jain, Rachit, Alberry, Ryan, Roquet, Nathaniel, Fu, Yanfang, Citorik, Robert J., Rubens, Jacob R., Holmes, Michael C., Cotta-Ramusino, Cecilia, Querbes, William, Alexander, Ian E., and Salomon, William E.
- Abstract
Recombinant adeno-associated virus (rAAV) vector gene delivery systems have demonstrated great promise in clinical trials but continue to face durability and dose-related challenges. Unlike rAAV gene therapy, integrating gene addition approaches can provide curative expression in mitotically active cells and pediatric populations. We explored a novel in vivodelivery approach based on an engineered transposase, Sleeping Beauty(SB100X), delivered as an mRNA within a lipid nanoparticle (LNP), in combination with an rAAV-delivered transposable transgene. This combinatorial approach achieved correction of ornithine transcarbamylase deficiency in the neonatal Spfashmouse model following a single delivery to dividing hepatocytes in the newborn liver. Correction remained stable into adulthood, while a conventional rAAV approach resulted in a return to the disease state. In non-human primates, integration by transposition, mediated by this technology, improved gene expression 10-fold over conventional rAAV-mediated gene transfer while requiring 5-fold less vector. Additionally, integration site analysis confirmed a random profile while specifically targeting TA dinucleotides across the genome. Together, these findings demonstrate that transposable elements can improve rAAV-delivered therapies by lowering the vector dose requirement and associated toxicity while expanding target cell types.
- Published
- 2024
- Full Text
- View/download PDF